C
Chau-Ting Yeh
Researcher at Memorial Hospital of South Bend
Publications - 256
Citations - 7862
Chau-Ting Yeh is an academic researcher from Memorial Hospital of South Bend. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 42, co-authored 225 publications receiving 6867 citations. Previous affiliations of Chau-Ting Yeh include Boston Children's Hospital & Chang Gung Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
Yao-Shih Hsu,Rong-Nan Chien,Chau-Ting Yeh,I-Shyan Sheen,Hung Yi Chiou,Chia-Ming Chu,Yun-Fan Liaw +6 more
TL;DR: It is suggested that spontaneous HBeAg seroconversion confers favorable long‐term outcomes, however, active hepatitis still may develop and lead to cirrhosis and HCC.
Journal ArticleDOI
Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
TL;DR: The results indicate that acute exacerbations may occur after emergence of the YMDD mutation, and possibly the underlying immune mechanisms, are similar to those of wild‐type HBV chronic infection.
Journal ArticleDOI
Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection
TL;DR: The long-term prognosis following acute HCV superinfection is much worse than that following HDV super Infection or active hepatitis B in terms of continuing hepatitis activity after HBsAg loss and the development of cirrhosis or hepatocellular carcinoma.
Journal ArticleDOI
Determinants for sustained HBeAg response to lamivudine therapy.
TL;DR: HBV genotype, age, and additional treatment are the major determinants for the sustained HBeAg response to lamivudine therapy.
Journal ArticleDOI
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
TL;DR: It is suggested that distinct lamivudine‐resistant mutants could emerge and replace the original YMDD‐motif mutants as the cause of continuing chronic hepatitis during prolonged lamivUDine therapy.